Kumar A et al. found that the expression of NLRP3 and its downstream components (caspase-1 and IL-1β) were enhanced in ccRCC, and LSD2 may be involved in the regulation of NLRP3 immunosomes in cancer cells, which could be a potential target for the treatment of ccRCC [36]. The gene discussed is NLRP3; the disease is nonpapillary renal cell carcinoma.